Does the media prefer COCH or VANI?

In the previous week, Vivani Medical had 1 more articles in the media than Envoy Medical. MarketBeat recorded 6 mentions for Vivani Medical and 5 mentions for Envoy Medical. Vivani Medical's average media sentiment score of 1.04 beat Envoy Medical's score of 0.47 indicating that Vivani Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envoy Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VANI or CGC?

Vivani Medical currently has a consensus price target of $3.75, suggesting a potential upside of 167.86%. Given Vivani Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Vivani Medical is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media favor VANI or CGC?

In the previous week, Canopy Growth had 6 more articles in the media than Vivani Medical. MarketBeat recorded 12 mentions for Canopy Growth and 6 mentions for Vivani Medical. Canopy Growth's average media sentiment score of 1.11 beat Vivani Medical's score of 1.04 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Canopy Growth 7 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VANI or FENC?

In the previous week, Adherex Technologies had 4 more articles in the media than Vivani Medical. MarketBeat recorded 10 mentions for Adherex Technologies and 6 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.04 beat Adherex Technologies' score of 0.67 indicating that Vivani Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation and earnings, AVIR or VANI?

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Vivani Medical N/A N/A -$26.61M -$0.40 N/A

Is AVIR or VANI more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Vivani Medical N/A -218.52% -73.92%

Does the media prefer AVIR or VANI?

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 6 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.18 beat Vivani Medical's score of 1.04 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VANI or ENTA?

In the previous week, Enanta Pharmaceuticals had 7 more articles in the media than Vivani Medical. MarketBeat recorded 13 mentions for Enanta Pharmaceuticals and 6 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.04 beat Enanta Pharmaceuticals' score of -0.44 indicating that Vivani Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Vivani Medical (VANI) Competitors

$1.40 +0.06 (+4.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 07:34 PM Eastern

Compare

VANI vs. COCH, CGC, FENC, AVIR, and ENTA

Should you buy Vivani Medical stock or one of its competitors? Vivani Medical's main competitors and comparable companies include Envoy Medical (COCH), Canopy Growth (CGC), Adherex Technologies (FENC), Atea Pharmaceuticals (AVIR), and Enanta Pharmaceuticals (ENTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Vivani Medical compare to Envoy Medical?

Envoy Medical (NASDAQ:COCH) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Envoy Medical has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Vivani Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-11,304.83%	N/A	-144.13%
Vivani Medical	N/A	-218.52%	-73.92%

In the previous week, Vivani Medical had 1 more articles in the media than Envoy Medical. MarketBeat recorded 6 mentions for Vivani Medical and 5 mentions for Envoy Medical. Vivani Medical's average media sentiment score of 1.04 beat Envoy Medical's score of 0.47 indicating that Vivani Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envoy Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envoy Medical has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$207K	297.12	-$23.76M	-$0.76	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

8.6% of Envoy Medical shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 7.1% of Envoy Medical shares are held by company insiders. Comparatively, 53.3% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Envoy Medical currently has a consensus target price of $2.25, suggesting a potential upside of 181.25%. Vivani Medical has a consensus target price of $3.75, suggesting a potential upside of 167.86%. Given Envoy Medical's higher possible upside, equities analysts plainly believe Envoy Medical is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Vivani Medical beats Envoy Medical on 9 of the 15 factors compared between the two stocks.

How does Vivani Medical compare to Canopy Growth?

Vivani Medical (NASDAQ:VANI) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Vivani Medical has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-218.52%	-73.92%
Canopy Growth	-65.33%	-21.91%	-14.34%

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vivani Medical has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Vivani Medical has higher earnings, but lower revenue than Canopy Growth. Vivani Medical is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
Canopy Growth	$251.01M	1.82	-$190.29M	-$0.45	N/A

Vivani Medical currently has a consensus price target of $3.75, suggesting a potential upside of 167.86%. Given Vivani Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Vivani Medical is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Canopy Growth had 6 more articles in the media than Vivani Medical. MarketBeat recorded 12 mentions for Canopy Growth and 6 mentions for Vivani Medical. Canopy Growth's average media sentiment score of 1.11 beat Vivani Medical's score of 1.04 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	7 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vivani Medical beats Canopy Growth on 8 of the 14 factors compared between the two stocks.

How does Vivani Medical compare to Adherex Technologies?

Vivani Medical (NASDAQ:VANI) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Vivani Medical has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -6.93% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-218.52%	-73.92%
Adherex Technologies	-6.09%	-6.93%	-2.48%

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vivani Medical has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Vivani Medical currently has a consensus target price of $3.75, indicating a potential upside of 167.86%. Adherex Technologies has a consensus target price of $16.40, indicating a potential upside of 39.93%. Given Vivani Medical's higher possible upside, equities research analysts clearly believe Vivani Medical is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Adherex Technologies has higher revenue and earnings than Vivani Medical. Adherex Technologies is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
Adherex Technologies	$44.64M	9.20	-$9.74M	-$0.13	N/A

In the previous week, Adherex Technologies had 4 more articles in the media than Vivani Medical. MarketBeat recorded 10 mentions for Adherex Technologies and 6 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.04 beat Adherex Technologies' score of 0.67 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Adherex Technologies beats Vivani Medical on 9 of the 15 factors compared between the two stocks.

How does Vivani Medical compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 6 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.18 beat Vivani Medical's score of 1.04 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atea Pharmaceuticals currently has a consensus target price of $7.00, suggesting a potential upside of 36.72%. Vivani Medical has a consensus target price of $3.75, suggesting a potential upside of 167.86%. Given Vivani Medical's higher possible upside, analysts plainly believe Vivani Medical is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Vivani Medical	N/A	-218.52%	-73.92%

Atea Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Atea Pharmaceuticals beats Vivani Medical on 7 of the 13 factors compared between the two stocks.

How does Vivani Medical compare to Enanta Pharmaceuticals?

Vivani Medical (NASDAQ:VANI) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Enanta Pharmaceuticals had 7 more articles in the media than Vivani Medical. MarketBeat recorded 13 mentions for Enanta Pharmaceuticals and 6 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.04 beat Enanta Pharmaceuticals' score of -0.44 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vivani Medical has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Enanta Pharmaceuticals' return on equity of -61.84% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-218.52%	-73.92%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

Vivani Medical currently has a consensus price target of $3.75, suggesting a potential upside of 167.86%. Enanta Pharmaceuticals has a consensus price target of $19.50, suggesting a potential upside of 48.18%. Given Vivani Medical's higher possible upside, equities analysts clearly believe Vivani Medical is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Vivani Medical has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vivani Medical has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
Enanta Pharmaceuticals	$65.32M	5.87	-$81.89M	-$2.41	N/A

Summary

Vivani Medical beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Vivani Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VANI vs. The Competition

Export

Metric	Vivani Medical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$115.56M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-4.00	775.15	269.06	25.28
Price / Sales	N/A	743.50	592.57	87.62
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	7.00	11.60	12.91	6.24
Net Income	-$26.61M	$2.77B	$3.45B	$347.60M
7 Day Performance	-0.71%	0.17%	1.12%	1.07%
1 Month Performance	N/A	0.35%	1.79%	1.03%
1 Year Performance	10.24%	161.52%	67.69%	20.77%

Vivani Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VANI Vivani Medical	3.8184 of 5 stars	$1.40 +4.5%	$3.75 +167.9%	+6.3%	$115.56M	N/A	N/A	20	News Coverage Positive News Earnings Report
COCH Envoy Medical	2.4287 of 5 stars	$0.77 +3.2%	$2.25 +192.2%	-49.6%	$59.43M	$240K	N/A	34	Earnings Report
CGC Canopy Growth	0.9 of 5 stars	$1.01 -0.5%	N/A	-38.4%	$450.66M	$251.01M	N/A	1,128	Positive News Earnings Report Analyst Downgrade
FENC Adherex Technologies	3.9068 of 5 stars	$11.91 -1.3%	$16.40 +37.8%	+32.4%	$418.62M	$44.64M	N/A	10	News Coverage Earnings Report Analyst Forecast Gap Up
AVIR Atea Pharmaceuticals	2.8314 of 5 stars	$5.13 +1.2%	$7.00 +36.5%	+44.9%	$410.55M	N/A	N/A	70	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VANI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivani Medical (VANI) Competitors

VANI vs. COCH, CGC, FENC, AVIR, and ENTA

How does Vivani Medical compare to Envoy Medical?

Summary

How does Vivani Medical compare to Canopy Growth?

Summary

How does Vivani Medical compare to Adherex Technologies?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Summary

How does Vivani Medical compare to Enanta Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivani Medical (VANI) Competitors

VANI vs. COCH, CGC, FENC, AVIR, and ENTA

How does Vivani Medical compare to Envoy Medical?

Which has more volatility and risk, COCH or VANI?

Is COCH or VANI more profitable?

Does the media prefer COCH or VANI?

Which has better valuation and earnings, COCH or VANI?

Do institutionals & insiders have more ownership in COCH or VANI?

Do analysts rate COCH or VANI?

Summary

How does Vivani Medical compare to Canopy Growth?

Is VANI or CGC more profitable?

Do institutionals and insiders hold more shares of VANI or CGC?

Which has more risk and volatility, VANI or CGC?

Which has preferable earnings and valuation, VANI or CGC?

Do analysts prefer VANI or CGC?

Does the media favor VANI or CGC?

Summary

How does Vivani Medical compare to Adherex Technologies?

Is VANI or FENC more profitable?

Do institutionals & insiders believe in VANI or FENC?

Which has more risk & volatility, VANI or FENC?

Do analysts rate VANI or FENC?

Which has better valuation and earnings, VANI or FENC?

Does the media favor VANI or FENC?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Which has stronger valuation and earnings, AVIR or VANI?

Does the media prefer AVIR or VANI?

Do analysts rate AVIR or VANI?

Is AVIR or VANI more profitable?

Which has more volatility & risk, AVIR or VANI?

Do institutionals and insiders hold more shares of AVIR or VANI?

Summary

How does Vivani Medical compare to Enanta Pharmaceuticals?

Does the media favor VANI or ENTA?

Is VANI or ENTA more profitable?

Do analysts recommend VANI or ENTA?

Which has more risk & volatility, VANI or ENTA?

Do insiders & institutionals have more ownership in VANI or ENTA?

Which has better valuation and earnings, VANI or ENTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools